Genmab A/S (NASDAQ:GMAB) Shares Gap Down – Time to Sell?

Genmab A/S (NASDAQ:GMAB)’s share price gapped down prior to trading on Monday . The stock had previously closed at $19.76, but opened at $19.01. Genmab A/S shares last traded at $19.09, with a volume of 178,264 shares.

Analysts Set New Price Targets

Several research firms have recently issued reports on GMAB. Leerink Partners upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating and set a $27.00 target price for the company in a report on Thursday, February 13th. BNP Paribas upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Tuesday, February 11th. William Blair upgraded shares of Genmab A/S from a “market perform” rating to an “outperform” rating in a report on Tuesday, March 11th. Leerink Partnrs upgraded shares of Genmab A/S from a “hold” rating to a “strong-buy” rating in a report on Thursday, February 13th. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a report on Friday, December 20th. Four research analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $41.33.

Genmab A/S Stock Performance

The firm’s fifty day moving average price is $21.04 and its 200 day moving average price is $22.12. The firm has a market cap of $12.72 billion, a P/E ratio of 11.05, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98.

Genmab A/S (NASDAQ:GMAB) last issued its quarterly earnings data on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.28 by $0.29. Genmab A/S had a net margin of 36.30% and a return on equity of 16.78%. As a group, analysts expect that Genmab A/S will post 1.45 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of GMAB. EverSource Wealth Advisors LLC grew its position in shares of Genmab A/S by 295.3% in the 4th quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company’s stock worth $26,000 after buying an additional 939 shares during the last quarter. Lindbrook Capital LLC grew its position in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company’s stock worth $39,000 after buying an additional 950 shares during the last quarter. GAMMA Investing LLC grew its position in Genmab A/S by 96.6% during the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Barclays PLC grew its position in Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company’s stock worth $52,000 after purchasing an additional 2,285 shares during the last quarter. Finally, Cromwell Holdings LLC grew its position in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company’s stock worth $60,000 after purchasing an additional 2,496 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.